SCHEMBL29926385

SCHEMBL29926385

CC(C)(O)Cn1cc(-c2nc(NC3CCN(S(=O)(=O)CCCCN4CCCCC4)CC3)ncc2C#N)cn1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 18/20 0.72
CDK2 P24941 18/20 0.72
CDK1 P06493 15/20 0.72
CCNB1 P14635 15/20 0.72
CCND1 P24385 14/20 0.72
CDK6 Q00534 14/20 0.72
CDK4 P11802 12/20 0.72
CCND3 P30281 12/20 0.72
CCNT1 O60563 9/20 0.72
CDK7 P50613 9/20 0.72
CDK9 P50750 9/20 0.72
CCNH P51946 9/20 0.72
MNAT1 P51948 9/20 0.72
CCNB2 O95067 2/20 0.41
CCNE2 O96020 2/20 0.41
CDK5 Q00535 2/20 0.41
CDK5R1 Q15078 2/20 0.41
CCNB3 Q8WWL7 2/20 0.41
JAK2 O60674 2/20 0.39
JAK1 P23458 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22901055 1.00 CCNE1 (0.72) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22900933 0.99 CCNE1 (0.73) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL29926620 0.99 CCNE1 (0.73) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL29927007 0.98 CCNE1 (0.73) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22901040 0.98 CCNE1 (0.73) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22901019 0.97 CCNE1 (0.74) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL29926319 0.97 CCNE1 (0.74) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22900961 0.88 CCNE1 (0.73) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL29926759 0.88 CCNE1 (0.73) CCNE1CDK2CDK1CCNB1CCND1
SCHEMBL22901093 0.87 CCNE1 (0.72) CCNE1CDK2CDK1CCNB1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11472791-B2 Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2022-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472791-B2 Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors CDK2, CDK2AP2, CDK4 CCNE1 42/4885CDK2 1/4885CDK1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.